Your session is about to expire
← Back to Search
Zilovertamab Vedotin + Standard of Care for Diffuse Large B-Cell Lymphoma
Study Summary
This trial is studying zilovertamab vedotin in combination with standard of care options for the treatment of rrDLBCL to see if it is more effective than standard of care alone.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have an active Hepatitis C infection.I can provide a new or stored tumor sample that hasn't been exposed to radiation.My slow-growing cancer has changed into aggressive large B-cell lymphoma.My previous CAR-T cell therapy did not work, or I am not eligible for it.I have a type of Charcot-Marie-Tooth disease that affects the nerve covering.My DLBCL is measurable by scans according to Lugano criteria.My DLBCL has returned or didn't respond to treatment, and I can't have or didn't benefit from a stem-cell transplant. I've tried at least one treatment before.My previous CAR-T cell therapy did not work, or I am not eligible for it.I have been diagnosed with primary mediastinal B-cell lymphoma.My lymphoma has not spread to my brain or spinal cord, or if it has, it's currently in remission.My DLBCL has returned or didn't respond to treatment, and I've tried at least 2 therapies.I am allergic or cannot tolerate some parts of the study treatment.I have fluid around my heart or in my lungs.My organs are functioning well.I had radiotherapy over 4 weeks ago and have recovered from all side effects.I haven't had cancer treatment or experimental drugs in the last 4 weeks.I have a serious heart condition that needs medication.I have ongoing nerve pain or tingling that affects my daily activities.I am currently being treated for an infection.I have been diagnosed with diffuse large B-cell lymphoma.I had another cancer but was treated successfully with no signs of it for 2 years.I am currently experiencing or being treated for graft-versus-host disease.I have not received a live vaccine in the last 30 days.I am currently on corticosteroid therapy.I can care for myself and am up and about more than half of my waking hours.
- Group 1: ZV + R-GemOx (Part 1)
- Group 2: ZV + R-GemOx (Part 2)
- Group 3: R-GemOx (active control for Part 2)
- Group 4: ZV + BR (Part 2)
- Group 5: Bendamustine Rituximab (BR)
- Group 6: ZV + BR (Part 1)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this clinical trial easy to find in major metropolitan areas?
"This trial is taking place at Louisiana State University Health Sciences Center New Orleans ( Site 0134) in Louisville, Louisiana, University of Massachusetts Medical School ( Site 0119) in New Orleans, Massachusetts, and New york Medical College ( Site 0113) in Worcester, New York along with 7 other locations."
What are the main diseases that Zilovertamab vedotin has been shown to be effective against?
"While zilovertamab vedotin is most often used as a dlbcl treatment, it has also shown efficacy in treating small cell lung cancer (sclc), head and neck carcinoma, and cervical cancers."
What is the efficacy of Zilovertamab vedotin in relation to other similar treatments?
"Zilovertamab vedotin was first studied at National Institutes of Health Clinical Center in 1993. So far, 2185 clinical trials have been completed, with 1197 active trials currently underway. Many of these trials are based in Louisville, Louisiana."
Are there any vacancies in this research project for new participants?
"The most recent information from clinicaltrials.gov suggests that this clinical trial is still looking for patients. The trial was initially posted on January 14th, 2022 and was last updated on October 24th, 2022."
How many participants are expected to join this research initiative?
"Yes, this is an ongoing study that is looking for 420 participants from 7 different locations. The trial was first announced on January 14th, 2022 and has since been updated on October 24th, 2022."
Share this study with friends
Copy Link
Messenger